Search for content, post, videos

Bactiguard starts new clinical study


Bactiguard and the Centre for Spinal Cord Injury are starting a new clinical trial, which aims to increase the quality of life for patients with spinal cord injury, who use urinary catheters.

“We are excited about the study and the possibility to improve the quality of life for these patients. Spinal cord injured patients are often at great risk of constantly being affected by painful urinary tract infections, which can be very limiting”, says Lena Lindbo, urotherapist and COO at the Centre for Spinal Cord Injury and Professor Åke Seiger, physician and R&D Manager at the Rehab Station Stockholm.

Many spinal cord injured patients have difficulties in emptying their bladder in a natural way and therefore use indwelling suprapubic urinary catheters. A large number of these patients suffer from recurrent urinary tract infections, requiring antibiotic treatment, which has a negative impact on their quality of life. In order to reduce the number of infections for these patients, Bactiguard is starting a clinical study together with the Centre for Spinal Cord Injury, Sweden’s leading clinic for spinal cord injured patients, at the Rehab Station Stockholm.

“We want to make a difference to these patients and reduce the suffering a urinary tract infection involves. In individual patient cases, within this patientgroup, it has already been documented that Bactiguard’s infection prevention catheters significantly reduce the risk of acquiring a urinary tract infection. We now hope to verify this further in a more comprehensive, high-quality study”, says Dorota Johansson, Director of R&D and Clinical Trials at Bactiguard.

The purpose of the study is to evaluate the effect of Bactiguard Infection Protection urinary catheters (BIP Foley Catheters) in the reduction of catheter-associated urinary tract infections and the need for antibiotic treatment for spinal cord injured patients with suprapubic indwelling catheters. The patients involved in this study are so-called high-risk patients, with at least three urinary tract infections during the past year. The outcome of the study will be based on a comparison of approximately six months use of a Bactiguard coated Foley catheter and approximately six months use of a standard catheter for each patient in the study.